Good News for Advanced Gastric Cancer Patients! This Oral Chemotherapy Drug Is Now Covered by Insurance, Saving Money and Worry with At-Home Treatment

For advanced gastric cancer patients whose disease progresses after first-line fluorouracil-based therapy, it is natural to feel anxious about the next steps. Don't worry—the 2025 national insurance negotiations bring good news! Oral paclitaxel solution has been successfully added to the insurance catalog. Its indication for advanced gastric cancer that progresses during or after first-line fluorouracil therapy is now officially covered. This not only lowers the drug price but also significantly reduces out-of-pocket costs after insurance reimbursement. In the future, treating gastric cancer will be less financially stressful, and you can use a convenient and effective medication at home!

Q: Is the treatment truly effective?
Living over 2 months longer, with greater hope for survival

When treating cancer, what matters most? Extending survival time while maintaining comfort. This oral paclitaxel solution achieves both. It utilizes a patented lipid self-emulsifying drug delivery technology (DH-LASED). Simply put, after taking the medicine, it reaches tumor cells through three pathways: tissue penetration, blood circulation, and lymphatic circulation, ensuring the drug works more effectively.

A domestic Phase III gastric cancer study shows that, compared to intravenous paclitaxel, the oral solution may extend survival (median overall survival increased by 2.59 months: mOS 9.13 vs. 6.54 months) and reduce the risk of death by 23% (HR 0.770, P=0.006). For context, the average overall survival for second-line advanced gastric cancer treatment is typically around 6–9 months.

Q: Will taking the medication be uncomfortable?
These troubling side effects have been significantly reduced

When it comes to chemotherapy, many patients fear infusion-related allergic reactions, as well as side effects like numbness in hands and feet, fatigue, and hair loss. This oral medication greatly improves these issues, making treatment much more tolerable.

—— No need to fear allergies: Previously, IV paclitaxel required premedication with steroids like dexamethasone to prevent allergic reactions and infusion reactions. With this oral drug, premedication is generally unnecessary due to the low allergy risk, bringing much peace of mind.

—— Fewer uncomfortable reactions: Peripheral neuropathy (numbness) occurs in only 22.3% of oral users compared to 38.7% with IV infusion—nearly half the rate. Fatigue is also reduced: 16.6% for oral vs. 24.4% for IV. Hair loss is less severe: 30.6% for oral vs. 48.5% for IV. Musculoskeletal pain drops from 22.6% to 7.2%. This means you can maintain your strength, worry less about appearance changes, and feel much better during treatment!

Q: Is it convenient to take?
Done in 3 minutes at home, without disrupting daily life

In the past, chemotherapy meant frequent hospital visits, long waits, and hours of infusion, often requiring family accompaniment and disrupting daily routines. It also increased the risk of hospital-acquired infections. This oral paclitaxel eliminates all that hassle!

The dosing schedule is straightforward: Each treatment cycle lasts 28 days. You only need to take the medication on days 1, 8, and 15 of each cycle. The dose is 200 mg/m², taken twice daily. No hospital visits, no IV lines—just 3–5 minutes at home. You can continue working and spending time with family without interruption.

A helpful tip: Rinse your mouth with water within 30 minutes after taking the dose to significantly reduce the risk of oral inflammation. The incidence of severe oral mucositis (grade ≥3) is only 1.9%, so this is rarely a major concern.

Q: Which patients can use it?
Covers most clinical situations

This medication has a broad range of applicability and is suitable for many patients regardless of their specific condition:

—— Post-gastrectomy patients: Whether you've had a partial or total stomach removal, the medication can still be used effectively.

—— Patients with metastases: Whether the cancer has spread to the liver, lymph nodes, or multiple organs (3+), the efficacy and safety remain reliable, largely thanks to the lymphatic absorption pathway mentioned earlier.

—— Physical condition: As long as your performance status (ECOG PS) is 0–2, you can generally tolerate the treatment well.

Q: What should I watch out for?
Certain conditions must be avoided

While this medication is highly beneficial, there are important precautions to keep in mind:

—— Strict contraindications: Do not use if you are allergic to paclitaxel or any excipients. Avoid if you have an active infection (e.g., fever, inflammation), as chemotherapy may worsen it. Pregnant women, those planning pregnancy, and breastfeeding mothers should not use it.

—— Pre-treatment evaluation: Before starting, your doctor will assess your physical condition (ECOG 0–2 required). Aside from hair loss, nausea, vomiting without antiemetics, and stomatitis, other symptoms should have recovered to a mild level (grade 1 or baseline). Blood counts, liver, and kidney function must also meet the prescribing guidelines to ensure safety.

—— Fluid restriction after dosing: Do not drink large amounts of water within 30 minutes after taking the medication. Limit fluid intake to 200 ml.

—— Dietary advice: You may eat normally after dosing, but avoid grapefruit, oranges, and their juices, as they can interfere with drug metabolism.

For advanced gastric cancer patients, the biggest fears after first-line treatment fails are the lack of effective drugs, high costs, and grueling treatment processes. Now that oral paclitaxel solution is covered by insurance, it addresses financial concerns, allows for convenient at-home administration, reduces suffering, and extends survival. Whether you are elderly, physically frail, post-gastrectomy, or have multiple metastases, this option is available. Moving forward, gastric cancer treatment offers a more worry-free and reassuring choice, freeing you from the burdens of traditional chemotherapy so you can better enjoy life!

This content is not intended as medical advice for disease treatment. Please consult your physician for diagnosis and treatment. Disclaimer.

Patient Stories | Click text to jump directly

Doctor-Patient Communication | Click text to jump directly

Peking University Cancer Hospital, Shen Lin: 肠癌免疫治疗进展2023 | 手把手教肠癌胃癌患者如何看病

Peking University Cancer Hospital, Xing Baocai: 肠癌肝转移医患交流

Fudan University Shanghai Cancer Center, Cai Guoxiang: 病友群交流答疑实录

Sun Yat-sen University Cancer Center, Guangzhou, Wang Fenghua: 病友群交流实录

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Xiao Jian: 晚期胃癌的化疗、靶向、免疫治疗

Beijing Friendship Hospital, Yao Hongwei: 直肠癌患者需要做的检查及如何看懂检查报告